FDA-approved March 19, 2026. For patients who have plateaued on standard Wegovy 2.4mg and need additional weight loss. 20.7% mean weight reduction in the STEP UP trial.
By Dr. Teja V. Surapaneni, MD, MS • Board-Certified Internal Medicine (ABIM) • Licensed NV, WA, OR, WI • May 2026
Wegovy HD (semaglutide 7.2mg) is a higher-dose injectable formulation of semaglutide, approved by the FDA on March 19, 2026. It is the same molecule as standard Wegovy — just at three times the currently approved injectable dose. It comes in a single-dose pen (7.2mg/0.75mL) and is injected once weekly.
20.7% mean weight loss at the studied endpoint (efficacy estimand — patients who stayed on treatment). Approximately 1 in 3 patients achieved ≥25% weight loss.
For context:
Wegovy HD is approved as a step-up dose only — not a starting dose. You must have tolerated semaglutide 2.4mg for at least 4 weeks before escalating.
It is appropriate for patients who:
Standard Wegovy side effects also occur with Wegovy HD, but there is one side effect significantly more common at the higher dose:
This is a meaningful jump. The sensation is generally described as skin hypersensitivity — touch, temperature, or fabric feeling more sensitive. It is not dangerous but can be distressing. Patients must be counseled before starting.
Wegovy HD is available through NovoCare Pharmacy. Self-pay pricing: approximately $399/mo.
Medical disclaimer: Educational content, not medical advice. Consult a physician before starting any prescription medication. Page medically reviewed by Teja V. Surapaneni, MD, MS — Board-Certified Internal Medicine (NV, WA, OR, WI). Last reviewed: May 2026.